Pneumocystis pneumonia in children

Paediatric Respiratory Reviews

Volumn 10, Issue 4, 2009, Pages 192-198

  Pyrgos, Vasilios ^a,b   Shoham, Shmuel ^b   Roilides, Emmanuel ^a,c   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Corticosteroids; Immunocompromised children; Pneumocystis pneumonia (pcp); T lymphocytes; Trimethoprim sulphamethoxazole

Indexed keywords

ANTIINFECTIVE AGENT; COTRIMOXAZOLE;

CHILD; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PNEUMOCYSTIS PNEUMONIA; REVIEW; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CHILD; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMONIA, PNEUMOCYSTIS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 76549122038     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2009.06.010     Document Type: Review

References (109)

1. Edman J.C., Kovacs J.A., Masur H., Santi D.V., Elwood H.J., Sogin M.L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988, 334:519-522.
2. Gona P., Van Dyke R.B., Williams P.L., et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006, 296:292-300.
3. Wakefield A.E., Stewart T.J., Moxon E.R., Marsh K., Hopkin J.M. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans R Soc Trop Med Hyg 1990, 84:800-802.
4. Pifer L.L., Hughes W.T., Stagno S., Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978, 61:35-41.
5. Olsson M., Lidman C., Latouche S., et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998, 36:1737-1740.
6. Medrano F.J., Montes-Cano M., Conde M., et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005, 11:245-250.
7. Thomas C.F., Limper A.H. Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
8. Vargas S.L., Ponce C.A., Gigliotti F., et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000, 38:1536-1538.
9. Hughes W.T. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982, 145:842-848.
10. Cheung Y.F., Chan C.F., Lee C.W., Lau Y.L. An outbreak of Pneumocystis carinii pneumonia in children with malignancy. J Paediatr Child Health 1994, 30:173-175.
11. de Boer M.G., Bruijnesteijn van Coppenraet L.E., Gaasbeek A., et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis 2007, 44:1143-1149.
12. Dutz W., Post C., Vessal K., Kohout K. Endemic infantile Pneumocystis carinii infection: the Shiraz study. Natl Cancer Inst Monogr 1976, 43:31-40.
13. Larsen H.H., von Linstow M.L., Lundgren B., Høgh B., Westh H., Lundgren J.D. Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007, 13:66-72.
14. Stagno S., Pifer L.L., Hughes W.T., Brasfield D.M., Tiller R.E. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics 1980, 66:56-62.
15. Vargas S.L., Ponce C.A., Hughes W.T., et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis 1999, 29:1489-1493.
16. Vargas S.L., Ponce C.A., Galvez P., et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J 2007, 26:81-83.
17. Keely S.P., Stringer J.R., Baughman R.P., Linke M.J., Walzer P.D., Smulian A.G. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995, 172:595-598.
18. Latouche S., Poirot J.L., Bernard C., Roux P. Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus-infected patients during one or several episodes of pneumonia. J Clin Microbiol 1997, 35:1687-1690.
19. Morris A., Lundgren J.D., Masur H., et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10:1713-1720.
20. Ansari N.A., Kombe A.H., Kenyon T.A., et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatr Infect Dis J 2003, 22:43-47.
21. Simonds R.J., Oxtoby M.J., Caldwell M.B., Gwinn M.L., Rogers M.R. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993, 270:470-473.
22. Mofenson L.M., Oleske J., Serchuck L., et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004, 53(RR-14):1-92.
23. Branten A.J., Beckers P.J., Tiggeler R.G., Hoitsma A.J. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant 1995, 10:1194-1197.
24. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71:5-13.
25. Arend S.M., Kroon F.P., van't Wout J.W. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995, 155:2436-2441.
26. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
27. Slivka A., Wen P.Y., Shea W.M., Loeffler J.S. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993, 94:216-219.
28. Overgaard U.M., Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007, 39:589-595.
29. Hughes W.T., Feldman S., Aur R.J., Verzosa M.S., Hustu H.O., Simone J.V. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975, 36:2004-2009.
30. Sepkowitz K.A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002, 34:1098-1107.
31. Byrd J.C., Hargis J.B., Kester K.E., Hospenthal D.R., Knustson S.W., Diehl L.F. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995, 49:135-142.
32. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004, 22:610-616.
33. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891-3897.
34. Arend S.M., Westendorp R.G., Kroon F.P., et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996, 22:920-925.
35. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151(3 Pt 1):795-799.
36. Godeau B., Coutant-Perronne V., Le Thi Huong T., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994, 21:246-251.
37. Kalyoncu U., Karadag O., Akdogan A., et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007, 39:475-478.
38. Seddik M., Meliez H., Seguy D., Viget N., Cortot A., Colombel J.F. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2004, 10:436-437.
39. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481-1484.
40. BenMustapha-Darghouth I., Trabelsi S., Largueche B., Bejaoui M., Dellagi K., Barbouche M.R. Prevalence of Pneumocystis jiroveci pneumonia in Tunisian primary immunodeficient patients. Arch Pediatr 2007, 14:20-23.
41. Winkelstein J.A., Marino M.C., Ochs H., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003, 82:373-384.
42. Imai K., Morio T., Zhu Y., et al. Clinical course of patients with WASP gene mutations. Blood 2004, 103:456-464.
43. Deerojanawong J., Chang A.B., Eng P.A., Robertson C.F., Kemp A.S. Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome. Pediatr Pulmonol 1997, 24:324-330.
44. Limper A.H., Martin W.J. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest. 1990, 85:391-396.
45. Limper A.H., Hoyte J.S., Standing J.E. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997, 99:2110-2117.
46. Linke M.J., Harris C.E., Korfhagen T.R., et al. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 2001, 183:943-952.
47. Neese L.W., Standing J.E., Olsen E.J., Castro M., Limper A.H. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-alpha in response to Pneumocystis carinii. J Immunol 1994, 152:4549-4556.
48. Hidalgo H.A., Helmke R.J., German V.F., Mangos J.A. Pneumocystis carinii induces an oxidative burst in alveolar macrophages. Infect Immun 1992, 60:1-7.
49. Steele C., Marrero L., Swain S., et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 2003, 198:1677-1688.
50. Tachado S.D., Zhang J., Zhu J., Patel N., Cushion M., Koziel H. Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2. J Leukoc Biol 2007, 81:205-211.
51. Ezekowitz R.A., Williams D.J., Koziel H., et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991, 351:155-158.
52. Koziel H., Eichbaum Q., Kruskal B.A., et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998, 102:1332-1344.
53. Phair J., Munoz A., Detels R., Kaslow R., Rinaldo C., Saah C. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990, 322:161-165.
54. Garvy B.A., Qureshi M.H. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J Immunol 2000, 165:6480-6486.
55. Jain A., Atkinson T.P., Lipsky P.E., Slater J.E., Nelson D.L., Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 1999, 103:1151-1158.
56. Beck J.M., Warnock M.L., Cutis J.L., et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 1991, 5:186-197.
57. Shellito J., Suzara V.V., Blumenfeld W., Beck J.M., Sterger H.J., Ermak T.H. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990, 85:1686-1693.
58. McAllister F., Steele C., Zheng M., et al. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol 2004, 172:1132-1138.
59. McKinley L., Logar A.J., McAllister F., Zheng M., Steele C., Kolls J.K., Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol 2006, 177:6215-6226.
60. Lund F.E., Schuer K., Hollifield M., Randall T.D., Garvy B.A. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J Immunol 2003, 171:1423-1430.
61. Lund F.E., Hollifield M., Schuer K., Lines J.L., Randall T.D., Garvy B.A. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006, 176:6147-6154.
62. Gigliotti F., Hughes W.T. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988, 81:1666-1668.
63. Ng V.L., Yajko D.M., Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997, 10:401-418.
64. Walzer P.D., Smulian A.G. Pneumocystis species. Principles, Practice of Infectious, Diseases 2005, 3080-3094. Elsevier Churchill Livingstone, Philadelphia. G.L. Mandell, J.E. Bennet, R. Dolin (Eds.).
65. Kovacs J.A., Hiemenz J.W., Macher A.M., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984, 100:663-671.
66. Masur H. Pneumocystosis. AIDS Therapy 2003, 403-418. Churchill Livingstone, Philadelphia. R. Dolin, R. Masur, M.S. Saag (Eds.).
67. Barry S.M., Lipman M.C., Deery A.R., Johnson M.A., Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002, 3:207-211.
68. Wislez M., Bergot E., Antoine M., et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001, 164:847-851.
69. Selwyn P.A., Pumerantz A.S., Durante A., et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. Aids 1998, 12:885-893.
70. Gruden J.F., Huang L., Turner J., et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997, 169:967-975.
71. Boiselle P.M., Crans C.A., Kaplan M.A. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol. 1999, 172:1301-1309.
72. DeLorenzo L.J., Huang C.T., Maguire G.P., Stone D.J. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987, 91:323-327.
73. Williams A.J., Duong T., McNally L.M., et al. Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. Aids 2001, 15:335-339.
74. Bakeera-Kitaka S., Musoke P., Downing R., Tumwine J.K. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr 2004, 24:227-235.
75. Sepkowitz K.A. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993, 17(Suppl 2):S416-422.
76. Cruciani M., Marcati P., Malena M., Bosco O., Serpelloni G., Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002, 20:982-989.
77. Ognibene F.P., Shelhamer J., Gill V., et al. The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis 1984, 129:929-932.
78. Golden J.A., Hollander H., Stulbarg M.S., Gamsu G. Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome. Chest 1986, 90:18-22.
79. Broaddus C., Dake M.D., Stulbarg M.S., et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 102:747-752.
80. Stokes D.C., Shenep J.L., Parhm D., Bozeman P.M., Marienchek W., Mackert P.W. Role of flexible bronchoscopy in the diagnosis of pulmonary infiltrates in pediatric patients with cancer. J Pediatr 1989, 115:561-567.
81. Huang L., Morris A., Limper A.H., Beck J.M. ATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006, 3:655-664.
82. Larsen H.H., Huang L., Kovacs J.A., et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004, 189:1679-1683.
83. Quist J., Hill A.R. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995, 108:415-418.
84. Tasaka S., Hasegawa N., Kobayashi S., et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007, 131:1173-1180.
85. Kawagishi N., Miyagi S., Satoh K., Akamatsu Y., Sekiguchi S., Satomi S. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007, 14:308-311.
86. Marty F.M., Koo S., Bryar J., Baden L.R. (1->3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007, 147:70-72.
87. Allegra C.J., Kovacs J.A., Drake J.C., Swan J.C., Chabner B.A., Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987, 165:926-931.
88. Huang L., Crothers K., Atzori C., et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis 2004, 10:1721-1728.
89. Winston D.J., Lau W.K., Gale R.P., Young L.S. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980, 92:762-769.
90. Rieder M.J., King S.M., Read S. Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997, 16:1028-1031.
91. Stein C.R., Poole C., Kazanjian P., Meshnick S.R. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004, 10:1760-1765.
92. Nahimana A., Rabodonirina M., Bille J., Francioli P., Hauser P.M. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 2004, 48:4301-4305.
93. Miller T.L., Winter H.S., Luginbuhl L.M., Orav E.J., McIntosh K. Pancreatitis in pediatric human immunodeficiency virus infection. J Pediatr 1992, 120(2 Pt 1):223-227.
94. Assan R., Perronne C., Assan D., et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995, 18:47-55.
95. Safrin S., Finkelstein D.M., Feinberg J., et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996, 124:792-802.
96. Sin D.D., Shafran S.D. Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:477-481.
97. Hughes W., Leoung G., Kramer F., et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993, 328:1521-1527.
98. Dohn M.N., Weinberg W.G., Torres R.A., et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med 1994, 121:174-180.
99. Sleasman J.W., et al. Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. Am J Dis Child 1993, 147:30-34.
100. Bye M.R., Cairns-Bazarian A.M., Ewig J.M. Markedly reduced mortality associated with corticosteroid therapy of Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome. Arch Pediatr Adolesc Med 1994, 148:638-641.
101. Delclaux C., Hemenway C., Klein A.S., Barrett D.J. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999, 29:670-672.
102. Pareja J.G., Garland R., Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998, 113:1215-1224.
103. Simonds R.J., Lindegren M.L., Thomas P., et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med 1995, 332:786-790.
104. Kaplan J.E., Masur H., Holmes K. Guidelines for the prevention of opportunistic infections among HIV-infected persons - 2002. MMWR Recomm Rep 2002, 51:1-52.
105. Nachman S., Gona P., Dankner W., et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005, 115:e488-494.
106. Esposito S., Bojanin K., Porta A., Cesati L., Gualtieri L., Pincipi N. Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2005, 24:1117-1120.
107. Fishman J.A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001, 33:1397-1405.
108. Rodriguez M., Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004, 17:770-782.
109. Gigliotti F., Wright T.W. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med 2005, 7:1-16.